Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Long-Term Debt Repayments (2017 - 2025)

Historic Long-Term Debt Repayments for Vistagen Therapeutics (VTGN) over the last 12 years, with Q4 2025 value amounting to $278000.0.

  • Vistagen Therapeutics' Long-Term Debt Repayments changed N/A to $278000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $642000.0, marking a year-over-year change of. This contributed to the annual value of $985000.0 for FY2024, which is 473.89% down from last year.
  • Latest data reveals that Vistagen Therapeutics reported Long-Term Debt Repayments of $278000.0 as of Q4 2025.
  • Vistagen Therapeutics' Long-Term Debt Repayments' 5-year high stood at $785000.0 during Q3 2023, with a 5-year trough of -$1000.0 in Q4 2023.
  • In the last 4 years, Vistagen Therapeutics' Long-Term Debt Repayments had a median value of $274000.0 in 2025 and averaged $250863.6.
  • Over the last 5 years, Vistagen Therapeutics' Long-Term Debt Repayments had its largest YoY gain of 15503.57% in 2023, and its largest YoY loss of 10032.18% in 2023.
  • Over the past 4 years, Vistagen Therapeutics' Long-Term Debt Repayments (Quarter) stood at $98500.0 in 2021, then surged by 215.53% to $310800.0 in 2022, then tumbled by 100.32% to -$1000.0 in 2023, then skyrocketed by 27900.0% to $278000.0 in 2025.
  • Its last three reported values are $278000.0 in Q4 2025, $274000.0 for Q3 2025, and $90000.0 during Q2 2025.